Literature DB >> 7925941

Dystroglycan is a binding protein of laminin and merosin in peripheral nerve.

H Yamada1, T Shimizu, T Tanaka, K P Campbell, K Matsumura.   

Abstract

alpha-Dystroglycan, a 156 kDa dystrophin-associated glycoprotein, binds laminin in skeletal muscle. Here we demonstrate that alpha-dystroglycan is a binding protein of laminin (A/B1/B2) and merosin (M/B1/B2) in peripheral nerve. Immunocytochemical analysis demonstrates the localization of alpha-dystroglycan and merosin surrounding myelin sheath of peripheral nerve fibers. Biochemical analysis demonstrates that the 120 kDa peripheral nerve alpha-dystroglycan binds merosin as well as laminin. The binding of laminin and merosin is Ca2+ dependent and is inhibited by NaCl and heparin. Recently, merosin was shown to be deficient in the peripheral nerve of dy mice which have defects in myelination. The interaction between alpha-dystroglycan and merosin may play a role in the regulation of Schwann cell myelination and/or maintenance of myelin sheath.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925941     DOI: 10.1016/0014-5793(94)00917-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  41 in total

1.  Structure of the C-terminal laminin G-like domain pair of the laminin alpha2 chain harbouring binding sites for alpha-dystroglycan and heparin.

Authors:  D Tisi; J F Talts; R Timpl; E Hohenester
Journal:  EMBO J       Date:  2000-04-03       Impact factor: 11.598

2.  Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins.

Authors:  J F Talts; Z Andac; W Göhring; A Brancaccio; R Timpl
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

3.  Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase.

Authors:  Peng Zhang; Huaiyu Hu
Journal:  Glycobiology       Date:  2011-09-19       Impact factor: 4.313

4.  Alternative splicing of agrin regulates its binding to heparin alpha-dystroglycan, and the cell surface.

Authors:  J J O'Toole; K A Deyst; M A Bowe; M A Nastuk; B A McKechnie; J R Fallon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

5.  AChR phosphorylation and aggregation induced by an agrin fragment that lacks the binding domain for alpha-dystroglycan.

Authors:  T Meier; M Gesemann; V Cavalli; M A Ruegg; B G Wallace
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

6.  PMP22 Regulates Cholesterol Trafficking and ABCA1-Mediated Cholesterol Efflux.

Authors:  Ye Zhou; Joshua R Miles; Hagai Tavori; Min Lin; Habibeh Khoshbouei; David R Borchelt; Hannah Bazick; Gary E Landreth; Sooyeon Lee; Sergio Fazio; Lucia Notterpek
Journal:  J Neurosci       Date:  2019-05-06       Impact factor: 6.167

7.  REGULATION of the EXTRACELLULAR MATRIX INTERACTOME by Trypanosoma cruzi.

Authors:  Tatiana C Cardenas; Candice A Johnson; Siddharth Pratap; Pius N Nde; Vyacheslav Furtak; Yuliya Y Kleshchenko; Maria F Lima; Fernando Villalta
Journal:  Open Parasitol J       Date:  2010

8.  Muscle-specific expression of LARGE restores neuromuscular transmission deficits in dystrophic LARGE(myd) mice.

Authors:  Jessica D Gumerson; Carol S Davis; Zhyldyz T Kabaeva; John M Hayes; Susan V Brooks; Daniel E Michele
Journal:  Hum Mol Genet       Date:  2012-12-06       Impact factor: 6.150

9.  Biochemical and biophysical changes underlie the mechanisms of basement membrane disruptions in a mouse model of dystroglycanopathy.

Authors:  Peng Zhang; Yuan Yang; Joseph Candiello; Trista L Thorn; Noel Gray; Willi M Halfter; Huaiyu Hu
Journal:  Matrix Biol       Date:  2013-02-27       Impact factor: 11.583

10.  The ABCA1 cholesterol transporter associates with one of two distinct dystrophin-based scaffolds in Schwann cells.

Authors:  Douglas E Albrecht; Diane L Sherman; Peter J Brophy; Stanley C Froehner
Journal:  Glia       Date:  2008-04-15       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.